Phathom Pharmaceuticals Q1 revenue more than doubles, beats estimates

Phathom Pharmaceuticals

30/04/2026 12:07

Overview

U.S. GI drugmaker's Q1 revenue more than doubled, beating analyst expectations

Outlook

Phathom maintains 2026 net revenue guidance of $320–$345 mln

Company expects operating profitability starting in Q3 and for full-year 2026

Phathom anticipates cash flow positivity in 2027

Result Drivers

VOQUEZNA PRESCRIPTION GROWTH - Q1 revenue growth driven by 115% increase in VOQUEZNA prescriptions year-over-year

COST DISCIPLINE - Operating expenses fell 40% year-over-year due to lower promotional and personnel costs

Company press release: ID:nGNX7v7rqP

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$58.30 mln
$57.03 mln (9 Analysts)
Q1 Adjusted EPS
Beat
-$0.18
-$0.32 (8 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Phathom Pharmaceuticals Inc is $25.50, about 116.5% above its April 29 closing price of $11.78

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)